Blood eosinophils predict inhaled fluticasone response in bronchiectasis
- PMID: 32398295
- DOI: 10.1183/13993003.00453-2020
Blood eosinophils predict inhaled fluticasone response in bronchiectasis
Conflict of interest statement
Conflict of interest: S. Aliberti reports grants and personal fees from Bayer Healthcare, Aradigm Corporation, Chiesi, INSMED and Grifols, personal fees from AstraZeneca, Basilea, Zambon, Novartis, Raptor, Actavis UK Ltd and Horizon, outside the submitted work. Conflict of interest: G. Sotgiu has nothing to disclose. Conflict of interest: F. Blasi reports personal fees from AstraZeneca, GSK, Guidotti Malesci, Grifols, Menarini, Novartis, Pfizer, Sanofi and Zambon, grants from Bayer, grants and personal fees from Chiesi and Insmed, outside the submitted work. Conflict of interest: L. Saderi has nothing to disclose. Conflict of interest: T. Posadas has nothing to disclose. Conflict of interest: M.A. Martinez Garcia has received grants and fees from Zambon, Chiesi, Vitalire, Grifols, Novartis and TEVA.
Comment in
-
Systemic effects of fluticasone on blood eosinophils in bronchiectasis.Eur Respir J. 2020 Sep 3;56(3):2002005. doi: 10.1183/13993003.02005-2020. Print 2020 Sep. Eur Respir J. 2020. PMID: 32883758 No abstract available.
-
Blood eosinophils do not predict inhaled budesonide response in bronchiectasis.Eur Respir J. 2020 Sep 3;56(3):2002210. doi: 10.1183/13993003.02210-2020. Print 2020 Sep. Eur Respir J. 2020. PMID: 32883760 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources